226 filings
Page 4 of 12
S-8
g2dudlfx 3c81l
2 Mar 22
Registration of securities for employees
4:48pm
EFFECT
1aas95w 1sag2
2 Mar 22
Notice of effectiveness
12:15am
EFFECT
xt5pt1003xm3p fto
2 Mar 22
Notice of effectiveness
12:15am
F-3/A
4080kxro r4sskosu1b
25 Feb 22
Shelf registration (foreign) (amended)
8:52am
CORRESP
lk91fkr
25 Feb 22
Correspondence with SEC
12:00am
UPLOAD
9n4lgn
23 Feb 22
Letter from SEC
12:00am
F-3
3okz1t35d2uogie9e
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
28zdvr4h
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
wnii7p8py nkugu
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
c2yi4h6icye 3r6a4
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
c1kghqnmgcoiu56v
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
y87z64h
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
gqbqb5px9n07 zq
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
5aad n437xh7otv7l
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
2ip qazcdjvd8x
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
424B7
u2ix2jjogpwf3vo1
23 Nov 21
Prospectus with selling stockholder info
4:06pm
EFFECT
1xf5we6uvay mf3q8ql8
23 Nov 21
Notice of effectiveness
12:15am
6-K
vws87
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
CORRESP
i7xsj4 tbiml472w3
19 Nov 21
Correspondence with SEC
12:00am
UPLOAD
hlbs05bl17g
17 Nov 21
Letter from SEC
12:00am